Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRd induction, transplant, consolidation, and lenalidomide-dexamethasone maintenance for high-risk smoldering multiple myeloma
2014-002948-40Phase 2Active
- Sponsor
- Fundación PETHEMA
- Start
- Feb 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, lenalidomide, dexamethasone and melphalan in smoldering multiple myeloma (SMM), sponsored by Fundación PETHEMA. Primary endpoint: Immunophenotypic complete remission rate (Flow-CR) at day +100 after induction and HDT-ASCT. Started Feb 2015; status: active.
02
Drugs
carfilzomiblenalidomidedexamethasonemelphalan
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on 2014-002948-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002948-40.